Finding 1236741 (2023-010)

Material Weakness Repeat Finding
Requirement
C
Questioned Costs
-
Year
2023
Accepted
2026-09-25
Audit: 412274
Auditor: CBIZ CPAS PC

AI Summary

  • Core Issue: UHU received $1,082,381 in advance drawdowns for R&D grants without proper documentation linking these amounts to actual, allowable costs.
  • Impacted Requirements: Federal regulations require that cash receipts for drawdowns be supported by evidence of incurred eligible expenditures and management review.
  • Recommended Follow-Up: Implement procedures to document estimates for advance drawdowns and ensure all requests are reviewed and approved, linking them to qualifying expenditures.

Finding Text

CRITERIA Recipients of federal grants are required by federal regulations to maintain documentation demonstrating that cash receipts correspond to drawdowns based on actual, allowable costs incurred. Drawdowns for Federal awards should be properly supported with relevant forms and reports to substantiate the costs incurred and evidence management review and approval. CONDITION AND CONTEXT For certain grants within the Research and Development (R&D) cluster, funds were received in advance of expenditures. Of the total $1,700,112 in expenditures for the R&D cluster, $1,082,381 was received as advance drawdowns. For these advance drawdowns, UHU was unable to provide documentation supporting the estimates used to determine the amounts requested or evidence that the cash receipts were supported by eligible grant expenditures incurred, as required by the terms of the awards. The available documentation only substantiates the receipt of cash; there was no documentation supporting the basis or methodology for the estimates used to determine the amounts requested in advance drawdowns. CAUSE This deficiency resulted from the lack of procedures to ensure that advance drawdown amounts were determined based on documented estimates, and to maintain adequate records supporting both the methodology for those estimates and their connection to eligible expenditures incurred under the federal awards. EFFECT OR POTENTIAL EFFECT We were unable to determine whether the federal funds received in advance and recorded as cash receipts during the year were based on allowable costs incurred. As a result, there is a risk that federal funds may have been drawn down prior to, or in excess of, eligible expenditures. This could result in noncompliance with federal regulations regarding advance funding and may lead to a potential misstatement of federal expenditures and the accuracy of the SEFA. RECOMMENDATION We recommend that UHU establish and implement procedures to ensure that all advance drawdowns are supported by documented estimates that clearly outline the methodology used and are tied to allowable costs anticipated to be incurred under the federal programs. Additionally, management should maintain records that demonstrate the connection between amounts requested and qualifying expenditures and ensure that all drawdown requests and related estimates are subject to appropriate review and approval prior to submission. This will help ensure compliance with federal regulations and improve the accuracy of the SEFA.

Corrective Action Plan

o Establish formal procedures for the preparation, review, and approval of federal drawdown requests. o Require drawdowns to be supported by documented eligible expenditures. o Require management review and approval of drawdown requests prior to submission. o Reconcile drawdown requests to expenditures and accounting records. o Maintain documentation supporting drawdown calculations and approvals. Periodically review cash management practices for compliance with federal requirements.

Categories

Allowable Costs / Cost Principles Cash Management Reporting

Other Findings in this Audit

  • 1236723 2023-009
    Material Weakness Repeat
  • 1236724 2023-009
    Material Weakness Repeat
  • 1236725 2023-009
    Material Weakness Repeat
  • 1236726 2023-009
    Material Weakness Repeat
  • 1236727 2023-009
    Material Weakness Repeat
  • 1236728 2023-009
    Material Weakness Repeat
  • 1236729 2023-009
    Material Weakness Repeat
  • 1236730 2023-009
    Material Weakness Repeat
  • 1236731 2023-009
    Material Weakness Repeat
  • 1236732 2023-009
    Material Weakness Repeat
  • 1236733 2023-010
    Material Weakness Repeat
  • 1236734 2023-010
    Material Weakness Repeat
  • 1236735 2023-010
    Material Weakness Repeat
  • 1236736 2023-010
    Material Weakness Repeat
  • 1236737 2023-010
    Material Weakness Repeat
  • 1236738 2023-010
    Material Weakness Repeat
  • 1236739 2023-010
    Material Weakness Repeat
  • 1236740 2023-010
    Material Weakness Repeat
  • 1236742 2023-011
    Material Weakness Repeat
  • 1236743 2023-011
    Material Weakness Repeat
  • 1236744 2023-011
    Material Weakness Repeat
  • 1236745 2023-011
    Material Weakness Repeat
  • 1236746 2023-011
    Material Weakness Repeat
  • 1236747 2023-011
    Material Weakness Repeat
  • 1236748 2023-011
    Material Weakness Repeat
  • 1236749 2023-011
    Material Weakness Repeat
  • 1236750 2023-011
    Material Weakness Repeat
  • 1236751 2023-012
    Material Weakness Repeat
  • 1236752 2023-012
    Material Weakness Repeat
  • 1236753 2023-012
    Material Weakness Repeat
  • 1236754 2023-012
    Material Weakness Repeat
  • 1236755 2023-012
    Material Weakness Repeat
  • 1236756 2023-012
    Material Weakness Repeat
  • 1236757 2023-012
    Material Weakness Repeat
  • 1236758 2023-012
    Material Weakness Repeat
  • 1236759 2023-012
    Material Weakness Repeat
  • 1236760 2023-013
    Material Weakness Repeat
  • 1236761 2023-013
    Material Weakness Repeat
  • 1236762 2023-013
    Material Weakness Repeat
  • 1236763 2023-013
    Material Weakness Repeat
  • 1236764 2023-013
    Material Weakness Repeat
  • 1236765 2023-013
    Material Weakness Repeat
  • 1236766 2023-013
    Material Weakness Repeat
  • 1236767 2023-013
    Material Weakness Repeat
  • 1236768 2023-013
    Material Weakness Repeat
  • 1236769 2023-013
    Material Weakness Repeat
  • 1236770 2023-014
    Material Weakness Repeat
  • 1236771 2023-014
    Material Weakness Repeat
  • 1236772 2023-014
    Material Weakness Repeat
  • 1236773 2023-014
    Material Weakness Repeat
  • 1236774 2023-014
    Material Weakness Repeat
  • 1236775 2023-014
    Material Weakness Repeat
  • 1236776 2023-014
    Material Weakness Repeat
  • 1236777 2023-014
    Material Weakness Repeat
  • 1236778 2023-014
    Material Weakness Repeat
  • 1236779 2023-014
    Material Weakness Repeat
  • 1236780 2023-015
    Material Weakness Repeat
  • 1236781 2023-016
    Material Weakness Repeat
  • 1236782 2023-016
    Material Weakness Repeat
  • 1236783 2023-016
    Material Weakness Repeat
  • 1236784 2023-016
    Material Weakness Repeat
  • 1236785 2023-016
    Material Weakness Repeat
  • 1236786 2023-016
    Material Weakness Repeat
  • 1236787 2023-016
    Material Weakness Repeat
  • 1236788 2023-016
    Material Weakness Repeat
  • 1236789 2023-016
    Material Weakness Repeat
  • 1236790 2023-016
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.914 HIV EMERGENCY RELIEF PROJECT GRANTS $827,117
93.243 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE $547,532
93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS $400,743
93.788 OPIOID STR $275,534
93.136 INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS $257,074
93.917 HIV CARE FORMULA GRANTS $58,312
93.242 MENTAL HEALTH RESEARCH GRANTS $41,967
93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH $25,429
93.940 HIV PREVENTION AND SURVEILLANCE ACTIVITIES-HEALTH DEPARTMENT BASED $4,314